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SUMMARY
Colonization with health care-associated pathogens such as
Staphylococcus aureus, enterococci, Gram-negative organisms,
and Clostridium difficile is associated with increased risk of infec-
tion. Decolonization is an evidence-based intervention that can be
used to prevent health care-associated infections (HAIs). This re-
view evaluates agents used for nasal topical decolonization, topical
(e.g., skin) decolonization, oral decolonization, and selective di-
gestive or oropharyngeal decontamination. Although the majority
of studies performed to date have focused on S. aureus decoloni-
zation, there is increasing interest in how to apply decolonization
strategies to reduce infections due to Gram-negative organisms,
especially those that are multidrug resistant. Nasal topical decolo-
nization agents reviewed include mupirocin, bacitracin, reta-
pamulin, povidone-iodine, alcohol-based nasal antiseptic, tea tree
oil, photodynamic therapy, omiganan pentahydrochloride, and
lysostaphin. Mupirocin is still the gold standard agent for S. aureus
nasal decolonization, but there is concern about mupirocin resis-
tance, and alternative agents are needed. Of the other nasal de-
colonization agents, large clinical trials are still needed to evaluate
the effectiveness of retapamulin, povidone-iodine, alcohol-based
nasal antiseptic, tea tree oil, omiganan pentahydrochloride, and
lysostaphin. Given inferior outcomes and increased risk of allergic
dermatitis, the use of bacitracin-containing compounds cannot be
recommended as a decolonization strategy. Topical decoloniza-
tion agents reviewed included chlorhexidine gluconate (CHG),
hexachlorophane, povidone-iodine, triclosan, and sodium hypo-
chlorite. Of these, CHG is the skin decolonization agent that has
the strongest evidence base, and sodium hypochlorite can also be
recommended. CHG is associated with prevention of infections
due to Gram-positive and Gram-negative organisms as well as
Candida. Conversely, triclosan use is discouraged, and topical de-
colonization with hexachlorophane and povidone-iodine cannot
be recommended at this time. There is also evidence to support
use of selective digestive decontamination and selective oropha-
ryngeal decontamination, but additional studies are needed to
assess resistance to these agents, especially selection for resistance
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among Gram-negative organisms. The strongest evidence for de-
colonization is for use among surgical patients as a strategy to
prevent surgical site infections.
INTRODUCTION
Health care-associated infections (HAIs) burden patients,complicate treatments, prolong hospital stays, increase costs,
and can be life-threatening. Up to 15% of patients develop an
infection while hospitalized. The Centers for Disease Control and
Prevention (CDC) report “Antibiotic Resistance Threats in the
United States, 2013” highlights that at least two million Americans
acquire severe antibiotic-resistant infections each year, which re-
sults in 23,000 deaths annually. Most deaths occur in health care
settings such as hospitals. That CDC report recommends attempt-
ing to prevent these infections through appropriate antibiotic use
and infection prevention practices (1). HAIs are now the fifth
leading cause of death in U.S. acute-care hospitals (2). The human
suffering and financial burden associated with these infections are
significant. Recent reports have estimated that U.S. health care
system direct costs that can be attributed to HAIs range from $9.8
billion to $45 billion per year (3–5). Beyond direct financial costs,
HAIs also contribute significantly to increased patient length of
stay in the hospital, which results in both financial costs and pa-
tient dissatisfaction.
Over the past several years, large changes in U.S. health care
have had an impact on HAI prevention. First, we now know that a
significant percentage of HAIs can be prevented by use of evi-
dence-based strategies (6). Second, there are now coordinated ef-
forts among federal agencies aimed at HAI prevention (7), includ-
ing public reporting of hospital-specific HAI rates (8) and linking
hospital-specific HAI performance measures to financial reim-
bursement in order to stimulate HAI prevention efforts. Since
2011, hospitals have been required to report to the CDC’s Na-
tional Healthcare Safety Network (NHSN) all of their central-line-
associated bloodstream infections (CLABSIs) among intensive
care unit (ICU) patients in order to qualify for annual payment
updates. The Centers for Medicare and Medicaid (CMS) also re-
quires hospitals to report new data to NHSN, including surgical
site infection (SSI) rates for colon surgery and abdominal hyster-
ectomy, methicillin-resistant Staphylococcus aureus (MRSA)
bloodstream infections, Clostridium difficile infections (CDI),
catheter-associated urinary tract infections (CAUTIs), and influ-
enza vaccination among health care workers. In addition, starting
in 2015, CLABSIs and CAUTIs must be reported hospital wide.
These data, as well as other quality metrics, will be used to deter-
mine CMS reimbursement levels for each hospital as a component
of value-based purchasing, thus creating performance-driven re-
imbursement (7, 8). Therefore, hospitals now have a financial in-
centive to implement prevention strategies to control HAIs. One
such prevention strategy is bacterial decolonization.
Bacteria have been part of the normal human microflora for
eons and usually do not cause signs or symptoms of infection (9).
This colonization is most common in body sites such as the nose,
skin, and gastrointestinal tract. The body sites of colonization are
usually specific to the type of bacteria. S. aureus and other com-
mensal Gram-positive organisms (e.g., coagulase-negative staph-
ylococci [CNS]) most commonly colonize the skin and mucosal
membranes of the nose (10). Both Gram-positive (e.g., Streptococ-
cus pneumoniae) and Gram-negative organisms colonize the
pharynx (11, 12). Other organisms, such as enterococci, C.
difficile, and Gram-negative organisms (e.g., Enterobacteriaceae),
commonly colonize the gastrointestinal tract (13).
Bacterial colonization can occur among both healthy and ill
populations. Between 15 and 30% of healthy adults are nasally
colonized with methicillin-susceptible S. aureus (MSSA), and 1%
to 3% are nasally colonized with MRSA (14–17). Hospitalized
patients and long-term-care facility residents are at high risk of
colonization with health care-associated pathogens. In 2012, a
survey of 143 Canadian hospitals found that among their inpa-
tients, 4.5% were colonized or infected with MRSA, 2.7% were
colonized or infected with vancomycin-resistant enterococci
(VRE), 1.4% were colonized or infected withC. difficile, 1.3% were
colonized or infected with an extended-spectrum -lactamase
(ESBL)-producing organism, and 0.1% were colonized or infected
with carbapenem-resistant Enterobacteriaceae (CRE) (18).
S. aureus colonization at other body sites, including the phar-
ynx, groin, perianal region, or axilla, is also associated with devel-
opment of S. aureus infections. This is most common among
high-risk groups such as ICU patients, men who have sex with
men, and HIV-infected patients (19–21). Similarly, gastrointesti-
nal colonization with VRE is associated with increased risk of VRE
infection (22–24). Even less-harmful bacteria that colonize the
skin, such as CNS, can lead to infections among immunosup-
pressed patients and patients undergoing surgery (25, 26).
Since colonization often leads to infection, two overarching
approaches to HAI prevention have emerged: (i) horizontal strat-
egies to broadly reduce the burden of all pathogens and (ii) vertical
approaches to reduce colonization or infection due to specific
pathogens (27) (Table 1). Vertical approaches are directed at a
single pathogen and often utilize active surveillance testing. This is
important because multidrug-resistant organisms (MDROs),
such as VRE, multidrug-resistant Gram-negative organisms,
MRSA, and C. difficile, are similar in that colonization precedes
infection, transmission occurs by direct or indirect contact, and
there are many more asymptomatic patients than infected pa-
tients. In addition, unrecognized colonized patients can serve as a
source of transmission (28).
Horizontal decolonization approaches can target all clinically
meaningful health care-associated bacteria, including S. aureus,
enterococci, Candida, and Gram-negative bacteria. Chlorhexi-
dine gluconate (CHG) skin decolonization of all high-risk patient
populations is an example of a horizontal strategy. Since CHG has
broad-spectrum activity, it has been shown to reduce infections
TABLE 1 Vertical and horizontal approachesa
Approach
Vertical (substantially reduces one pathogen; is pathogen specific)
Active surveillance (e.g., for MRSA, VRE, C. difficile, Gram-negative
MDROs)
Contact precautions (e.g., for MRSA/VRE colonization or MRSA/VRE
infection, C. difficile infection, Gram-negative MDROs)
Decolonization (e.g., for MRSA)
Horizontal (substantially reduces all infections; is not pathogen specific)
Standard precautions (HH, cough etiquette, PPE, universal gloving)
Bundles of care (e.g., CLABSI, SCIP, ventilator)
CHG bathing
Selective digestive tract decontamination
a Based on data from reference 27. HH, hand hygiene; PPE, personal protective
equipment; SCIP, surgical care improvement project.
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due to Gram-positive, Gram-negative, and Candida organisms.
Reducing the bioburden through the use of CHG can also prevent
blood culture contamination caused by skin commensals (e.g.,
coagulase-negative staphylococci), which may reduce the addi-
tional costs and unnecessary antibiotic treatment associated with
blood culture contamination (29). Selective digestive tract decon-
tamination (SDD) is another horizontal decolonization strategy
to prevent hospital-acquired respiratory tract infections.
Horizontal decolonization approaches have the potential to
eradicate multiple pathogens from a cocolonized patient. Cocolo-
nization with more than one type of bacteria is common because
some risk factors for colonization are common to multiple
MDROs (30). One recent study found that among nursing home
residents with indwelling devices, those colonized with multi-
drug-resistant Acinetobacter baumannii had a high likelihood of
also being colonized with another antibiotic-resistant Gram-neg-
ative pathogen (31). Similarly, other studies have found that ICU
patients colonized with VRE are often cocolonized with ESBL-
producing bacteria or with MRSA (30, 32). Colonization of mul-
tiple body sites is also seen frequently. One study found that the
likelihood of developing an MRSA infection increases as more
body sites are MRSA colonized (19).
Colonization can lead to infections in the colonized person and
transmission from person to person via direct or indirect contact.
Colonizing bacteria can be transmitted from healthy carriers to
uncolonized people, such as between members of the same house-
hold or the same long-term-care facility. They can also be trans-
mitted between sick patients via the hands of health care workers
and shared hospital environments such as bed rails (33). Illness
that leads to immunodeficiency, invasive procedures such as sur-
gery or central lines, and high-risk activities are associated with the
transition from harmless colonization to harmful infection (22,
34). Decolonization strategies aim to decrease the bacterial bur-
den in order to prevent transmission and infection. Often, these
strategies are vertical strategies in which patients are screened for
certain pathogens of interest (e.g., MRSA or VRE) and decolo-
nized if they are found to carry those pathogens. This may prevent
both endogenous and exogenous infections.
Endogenous infections occur when a colonizing isolate enters a
different body site on the same person and causes an infection.
These infection sites include open cuts or wounds, surgical sites,
and device sites. Patients who are nasally colonized with S. aureus
are more than twice as likely to develop an S. aureus infection as
noncolonized patients (10, 22, 34). Bacterial colonization can be
categorized as persistent carriage, intermittent carriage, or non-
carriage (14). One study of nursing home residents with indwell-
ing devices found that of the 15% who were colonized with mul-
tidrug-resistant Acinetobacter baumannii, nearly half of those
colonizations recurred over time (31). Other studies have shown
that among S. aureus nasal carriers, approximately 40% are per-
sistently colonized and 60% are intermittently colonized (14).
Those who are persistently colonized with S. aureus are at a higher
risk of infection than intermittent carriers or noncarriers (35).
One study found that among S. aureus carriers who were decolo-
nized and then exposed to a mixture of S. aureus strains, persistent
carriers preferentially reselected the same strain with which they
were previously colonized (36).
Exogenous infections occur when the infecting bacteria does
not come from a patient’s own flora but rather comes from an-
other person or the surrounding environment. This can occur in
hospitals, in long-term-care facilities, or in the community. Close
quarters, open wounds, devices, and suboptimal health care
worker hand hygiene and environmental cleaning are risk factors
for exogenous infections (33, 34).
Increasing antibiotic resistance among health care-associated
pathogens and the lack of new antibiotics in the developmental
pipeline have led to a focused effort to prevent, rather than solely
treat, HAIs. Many interventions to prevent HAIs, such as isola-
tion, protect only against exogenous infections. However, decolo-
nization is a potentially useful prevention strategy against both
endogenous and exogenous infections (37). Thus, the colonized
patient and, potentially, the surrounding patients both benefit.
The two most common methods of decolonization are application
of antimicrobial ointment to the nose and of antimicrobial body
washes to the skin. These have been shown to reduce infections in
specific subsets of patients, such as surgical, dialysis, long-term-
care, and ICU patients, although results vary depending on the
pathogen and the host (26, 38–44).
The goal of decolonization is to reduce or eliminate the bacte-
rial load on the body. Carriers with high bacterial loads are at
higher risk of infection and are more likely to transmit the bacteria
to their environments (14, 45). Persistent S. aureus carriers have
been found to carry a greater quantity of S. aureus in their noses
(measured in log10 CFU per nares culture) than intermittent car-
riers (46). Average S. aureus bacterial loads among nasal carriers
tend to range between 1.8 and 2.9 log10 CFU per nares culture (47,
48). One study found that this load increased among MRSA car-
riers when patients received antibiotics that did not have activity
against MRSA (e.g., beta-lactams or fluoroquinolones) (48). They
hypothesized that this may be due to either suppression of normal
flora such as CNS, leading to overgrowth of MRSA, or an increase
in the expression of MRSA adherence factors that promote colo-
nization (48). Another study found that higher log counts of
MRSA in the nose were associated with an increased likelihood of
colonization at other body sites and a greater likelihood of high log
counts at those body sites (49). That study found that mean extra-
nasal MRSA loads ranged from 0.87 log10 CFU per culture in the
axilla to 1.65 log10 CFU per culture in the perineum to 1.70 log10
CFU per culture in the groin (49). Some decolonizing agents claim
to completely eliminate the bacterial load from their application
sites, while others claim to only decrease the load. Yet, there are
few data on the level to which the bacterial load must be reduced in
order to prevent transmission and infections.
Decolonization is the most effective among patient popula-
tions who are at risk of infection for only a short period of time
(50). These include populations such as surgical patients, who
may be at a lower risk of infection after surgical closure and sur-
gical wound healing, and ICU patients, who are at a much lower
risk once they are discharged from the ICU. This window of time
is important because of concern regarding both recolonization
and resistance to colonizing agents. Thus, patient populations
who are at risk for only short periods of time can achieve short-
term success with decolonization (50).
Studies have found that patients tend to become recolonized
with S. aureus within weeks or months of being decolonized (51,
52). In fact, S. aureus recolonization rates at 1 year approached
50% for health care workers and 75% for patients on peritoneal
dialysis (53). Similarly, one study found that the S. aureus recolo-
nization rate at 4 months was 56% in patients on hemodialysis
(54). The goal of this paper is to review the evidence for different
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decolonization strategies on preventing HAIs. Most studies of de-
colonization have reported only on S. aureus decolonization; thus,
much of this review will focus on S. aureus decolonization.
NASAL TOPICAL DECOLONIZATION STRATEGIES
Mupirocin
Mupirocin is a topical antibacterial agent made up of pseu-
domonic acids produced by the bacterium Pseudomonas fluore-
scens. This agent inhibits synthesis of bacterial proteins by revers-
ibly binding to bacterial isoleucyl-tRNA synthetase. It has
excellent activity against staphylococci, most streptococci, and
Gram-negative organisms, including Neisseria gonorrhoeae, Hae-
mophilus influenzae, and Moraxella catarrhalis (55). There are two
different formulations of mupirocin, depending on the vehicle.
The first is a nasal ointment in petrolatum. The second is a generic
topical ointment that utilizes a polyethylene glycol vehicle. Both
have been used for nasal decolonization; however, the generic top-
ical ointment may be used more frequently due to its lower cost.
Side effects are uncommon and are mostly local site reactions
such as stuffy nose or burning or stinging of the nose. A ran-
domized controlled trial (RCT) comparing mupirocin against
a placebo found that 83% of the mupirocin group were decolo-
nized, compared with only 27% of the placebo group (P 
0.001). That trial also found that 81% of carriers who received
three to five doses of mupirocin were decolonized, compared
with 93% of carriers who received six or more doses of mupi-
TABLE 2 Characteristics of representative studies that have contributed to the evidence basea
Category and treatment
First author, yr
(reference) Study design Decolonizationb Study population Sample size
Methodology utilized for
testing
Nasal
Mupirocin Perl, 2002 (56) RCT Universal Surgical patients 3,864 “Nasal culture”
Mody, 2003 (43) RCT Targeted Long-term-care facility
residents (persistent
S. aureus carriers)
127 Standard culture, susceptibility
testing using E-tests
Schweizer, 2015 (152) QE time series
design
Targeted Surgical patients 42,534 Varied
Retapamulin Naderer, 2008 (82) RCT Targeted Persistent S. aureus
carriers
43 Not stated
Nasal povidone-iodine Phillips, 2014 (84) RCT Universal Surgical patients 1,697 “Nasal culture”
Bebko, 2015 (85) QE Universal Surgical patients 709 Not stated
Topical
Topical chlorhexidine
gluconate
Climo, 2013 (26) Cluster randomized
trial
Universal ICU patients 7,727 Either standard culture-based
or molecular-based (PCR)
methods
Huang, 2013 (40) Cluster randomized
trial
Universal and
targeted
ICU patients 74,256 Varied
Milstone, 2013 (109) Cluster randomized
crossover study
Universal Pediatric ICU patients 4,947 Not stated
Derde, 2014 (110) QE/cluster randomized
trial
Universal ICU patients 8,976 Varied
Sodium hypochlorite Fritz, 2011 (125) RCT Targeted Patients with S. aureus
CA-SSTI
300 Standard culture and
susceptibility testing
SDD/SOD de Smet, 2009 (140) Cluster randomized
crossover study
Universal Mechanically ventilated
ICU patients
5,939 Cultures with selective media
and susceptibility testing
Saidel-Odes, 2012 (146) RCT Targeted CRKP carriers 40 Chromogenic agar plus
susceptibility testing with
Hodge test and E-tests
Huttner, 2013 (145) RCT Targeted ESBL-E carriers 54 Chromogenic agar confirmed
by MALDI-TOF MS plus
susceptibility testing with
double-disc synergy test
Oostdijk, 2014 (142) Cluster randomized
crossover study
Universal ICU patients 9,800 “Surveillance culture”
a Abbreviations: RCT, randomized controlled trial; QE, quasi-experimental; ICU, intensive care unit; CHG, chlorhexidine gluconate; PI, povidone-iodine; RET, retapamulin;
MRSA, methicillin-resistant Staphylococcus aureus; MSSA, methicillin-susceptible Staphylococcus aureus; VRE, vancomycin-resistant enterococci; HRE, highly resistant
Enterobacteriaceae; ESBL-E, extended-spectrum -lactamase-producing Enterobacteriaceae; MALDI-TOF MS, matrix-assisted laser desorption ionization–time of flight mass
spectrometry; CRKP, carbapenem-resistant Klebsiella pneumoniae; CA-SSTI, community-associated skin and soft tissue infection.
b Targeted decolonization was defined as only colonized patients receiving the decolonizing agent; universal decolonization was defined as all patients receiving the decolonizing
agent regardless of colonization status.
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rocin (P  0.001) (56) (Table 2). Currently, mupirocin is rec-
ommended to be applied to the anterior nares twice daily for 5
days.
Nasal mupirocin is the most widely used topical antibacterial
agent. A systematic literature review evaluated 23 clinical trials,
including 12 trials that evaluated topically applied antibiotics. The
authors concluded that short-term nasal mupirocin was the most
effective treatment for MRSA decolonization, with success rates of
90% at 1 week after treatment and approximately 60% after a
longer follow-up time (57). The effectiveness of mupirocin was
similar for both MSSA and MRSA carriers.
Multiple studies have shown that mupirocin is effective in erad-
icating S. aureus nasal colonization, resulting in decreased num-
bers of infections among patients in high-risk settings such as
ICUs and hemodialysis, surgical, and long-term-care settings (39,
41, 42, 58). Mody et al. (43) published a double-blinded, placebo-
controlled RCT assessing the efficacy of nasal mupirocin in reduc-
ing colonization and preventing infections in two long-term-care
centers. Twice-daily treatment was given for 2 weeks, and patients
were followed for 6 months. After treatment, 93% of residents
who received mupirocin were decolonized, compared with only
15% in the placebo group (P 0.001). At 90 days after treatment,
61% of those receiving mupirocin remained decolonized. Addi-
tionally, there was a trend, though not statistically significant, to-
ward a reduction in infections. Thus, mupirocin may be effective
at eradicating persistent colonization in long-term care.
Two systematic literature reviews and meta-analyses of pub-
lished studies found a protective effect of mupirocin decoloniza-
tion against surgical site infections (SSIs), especially among non-
general surgery such as cardiac surgery, orthopedic surgery, and
neurosurgery (38, 42). (see Decolonization Prior to Surgery below
for additional information) Two other meta-analyses found that
decolonization with nasal mupirocin alone or in combination
with topical agents such as CHG decreased the odds of S. aureus
infection by approximately 60% among dialysis patients (39, 44).
This was due to a reduction in both exit-site infections and cath-
TABLE 2 (Continued)
Body site(s) screened
Pathogen(s) screened
for Duration of follow-up Other interventions Decolonization/recolonization assessed
Nose (but all patients
decolonized regardless)
MRSA, MSSA 30 days CHG shower (cardiac
patients only)
Yes; 93% decolonized in mupirocin group,
27.4% decolonized in placebo group
Nose and wounds MRSA, MSSA 6 mo None Yes; at 90 days 61% of mupirocin group and
18% of the placebo group were still
decolonized; at 6 mo too few residents
remained to draw conclusions
Nose MRSA, MSSA 90 days CHG bathing, vancomycin
for MRSA carriers
No
Nose S. aureus 28 days None Yes; 28 days later 75% decolonized in 3-day RET
group, 86% decolonized in 5-day RET group,
31% decolonized in placebo group
Nose (but all patients
decolonized regardless)
MRSA, MSSA 3 mo (7–31 days for
colonization)
CHG bathing, vancomycin
for MRSA carriers
Yes; 7–31 days later 92% decolonized in
mupirocin group and 54% decolonized in PI
group
Nose (but all patients
decolonized regardless)
MRSA 30 days (day after surgery
for colonization)
CHG bathing, oral rinse Yes; the day after surgery 469 patients were
tested, 2.2% of PI group carried MRSA and
5.7% of control group carried MRSA
Nose, perirectal area (but all
patients decolonized
regardless)
MRSA, VRE Hospitalization None No
Nose MRSA Hospitalization Intranasal mupirocin No
None None Hospitalization None No
Perineum, nose, wounds (but
all patients decolonized
regardless)
MRSA, VRE, HRE Hospitalization Hand hygiene
improvement
No
Nose, axilla, inguinal folds MRSA, and MSSA 4 mo Education and intranasal
mupirocin
Yes; at 4 mo S. aureus was eradicated from 48%
of controls and 71% of the bleach-mupirocin
group
Throat, rectum, sputum Gram-negative bacteria,
MRSA, VRE
28 days (8 for
colonization)
None Yes; rate cultures positive for Gram-negative
bacteria declined from day 2 to day 8 for both
SDD and SOD patients
Rectum, urine, groin, throat CRKP 6 wk None Yes; 6 wk later 33% in placebo group and 58% in
SDD group had negative rectal cultures
Rectum, urine, groin ESBL-E 28 days None Yes; 52% of treatment group and 37% of
placebo group had eradicated ESBL-E
carriage
Rectum, oropharynx,
endotracheal aspirates
Gram-negative bacteria,
VRE
28 days None Yes; over time the prevalence of highly resistant
microorganisms increased during SOD and
SDD
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eter-related bloodstream infections (39). Decolonization was as-
sociated with decreased numbers of infections among both hemo-
dialysis patients and peritoneal dialysis patients (39).
A Cochrane review aimed to determine whether the use of
mupirocin among S. aureus carriers reduced S. aureus infections.
Only RCTs comparing a mupirocin group with a control group
that received either no treatment, placebo, or an alternative nasal
treatment were included. The authors found that mupirocin was
associated with a significant reduction in S. aureus infections (rel-
ative risk [RR] 0.55; 95% confidence interval [CI], 0.43 to 0.70)
(58). However, Ellis et al. (59) performed a cluster randomized
study to evaluate whether intranasal mupirocin treatment for
community-associated MRSA (CA-MRSA)-colonized soldiers
could prevent infections in those who received mupirocin and
would prevent new colonization and infection in their cluster.
Although they found that CA-MRSA was eradicated in colonized
soldiers, they failed to show a decrease in infections in the mupi-
rocin-treated soldiers or within their cluster. Furthermore, CA-
MRSA decolonization did not prevent new colonization. This
study suggests that strategies to prevent CA-MRSA in these pop-
ulations may require interventions other than mupirocin decolo-
nization, such as hygiene education and CHG bathing (59–61).
This may be explained by studies suggesting that nasal coloniza-
tion may play a less prominent role in pathogenesis and transmis-
sion of CA-MRSA. Direct person-to-person and fomite-to-per-
son transmission appears to be an important route for CA-MRSA
infections (62). Popovich et al. demonstrated that inguinal and
perirectal colonization appears to be more frequent with the
USA300 strain (the most common genotype of CA-MRSA as de-
termined by pulsed-field gel electrophoresis [PFGE]) and that pa-
tients with clinical CA-MRSA infections appear to be colonized at
more than one site (63).
Mupirocin resistance among S. aureus has now been identified
in multiple studies, especially with widespread use over prolonged
periods (64–66). There are two phenotypes of mupirocin resis-
tance: low-level mupirocin resistance (LL-MR), with MICs from 8
to 64 g/ml, and high-level mupirocin resistance (HL-MR), with
MICs of 512 g/ml (67). S. aureus isolates with MICs between
64 and 512g/ml are uncommon (68). LL-MR results from point
mutations in the native chromosomal isoleucyl RNA synthetase
gene ileS (69, 70). The precise mechanism that confers low-level
resistance has not been fully defined, but there are some data to
suggest that there are changes in the tertiary structure of the en-
zyme that may reduce the binding affinity of mupirocin (70).
HL-MR results from acquisition of plasmid-mediated mupA,
which encodes a novel isoleucyl RNA synthetase (69).
Caffrey et al. (71) reported risk factors for mupirocin-resistant
MRSA. They matched 40 mupirocin-resistant cases to 270 con-
trols. In their adjusted conditional logistic regression model, they
found three risk factors: mupirocin exposure in the prior year
(odds ratio [OR] 9.84; 95% CI, 2.93 to 33.09), infection in the
prior year with Pseudomonas aeruginosa (OR 4.85; 95% CI, 1.20
to 19.61), and use of cefepime in the prior year (OR 2.80; 95%
CI, 1.03 to 7.58). A sensitivity analysis found that prior mupirocin
exposure was associated with both LL-MR and HL-MR. Thus,
prior mupirocin use is associated with mupirocin-resistant MRSA
(71).
More importantly, studies have shown that high-level mupiro-
cin-resistant S. aureus results in decolonization failure. The asso-
ciation between LL-MR and failure of mupirocin decolonization
is unclear. Walker et al. (72) published a prospective study to
determine the efficacy of nasal mupirocin in decolonizing patients
with mupirocin-susceptible MRSA (MS MRSA) and mupirocin-
resistant MRSA, both LL-MR MRSA and HL-MR MRSA. Patients
received 2% mupirocin twice daily for 5 days. They were then
cultured at day 3 and weeks 1, 2, and 4 after treatment. Nares
cultures at day 3 posttreatment were negative for 79% of patients
who had MS MRSA, 80% of patients who had LL-MR MRSA, and
28% of patients who had HL-MR MRSA. However, at the fol-
low-up 1 to 4 weeks later, the sustained decolonization for patients
with HL-MR MRSA and LL-MR MRSA was low (25% each, com-
pared to 91% in patients colonized with MS MRSA). This result
suggests that mupirocin probably temporally suppresses growth
of LL-MR MRSA but does not result in sustained decolonization.
Posttreatment cultures usually had the same genotype and suscep-
tibility phenotypes as the corresponding baseline cultures. This
appears to show endogenous recolonization and not exogenous
colonization.
The use of mupirocin, especially mupirocin applied repeatedly
to dialysis exit sites to prevent infections in chronic dialysis pa-
tients, is associated with HL-MR S. aureus exit-site infections (65,
73). One study evaluated mupirocin resistance among residents of
New Zealand, where mupirocin was available over the counter
from the years 1991 to 2000. They reported an increase in mupi-
rocin resistance, reaching 28% by 1999, with the highest rates
among community-acquired isolates (74). Resistance has been
shown to emerge in facilities with unrestrictive policies in which
widespread use of mupirocin is allowed for long periods of time,
such as if applied to decubitus ulcers (66). One study reported on
mupirocin resistance trends and documented a statistically signif-
icant increase in HL-MR isolates. An associated case-control study
demonstrated that the presence of a decubitus ulcer was associated
with HL-MR isolates (P 0.05) (66).
In contrast to unrestrictive use, short-term use of nasal mupi-
rocin for perioperative prophylaxis to prevent S. aureus SSIs has
not been associated with increased mupirocin resistance. Perl et al.
treated over 2,000 patients with mupirocin, performed mupirocin
susceptibility testing, and found that only 6 of the 1,021 isolates
(0.6%) were mupirocin resistant (56). Another study described
the results of repeated point-prevalence surveys over 4 years to
determine if mupirocin resistance had emerged in surgical units
using preoperative prophylaxis with 5 days of nasal mupirocin.
They found no evidence of sustained emergence or spread of
mupirocin resistance. No HL-MR strains were identified (75). Fi-
nally, a Dutch study evaluated over 20,000 patients who received
mupirocin prophylaxis for major cardiothoracic surgery. No
mupirocin resistance emerged (41).
To summarize, mupirocin is currently the best option for topicalS.
aureus nasal decolonization. Yet, the use of mupirocin has led to
mupirocin resistance and treatment failures, specifically with wide-
spread use over long periods of time. Therefore, alternatives to mupi-
rocin for eradication of MRSA among patients colonized or infected
with mupirocin-resistant strains are needed, and it is important to
evaluate newer agents or alternative methods of decolonization (76).
These alternative agents are described below.
Bacitracin
The topical agent bacitracin is produced from Bacillus subtilis. It
acts against MRSA and other Gram-positive bacteria by interfer-
ing with bacterial cell wall synthesis. Soto et al. performed an RCT
Septimus and Schweizer
206 cmr.asm.org April 2016 Volume 29 Number 2Clinical Microbiology Reviews
 o
n
 Septem
ber 12, 2018 by guest
http://cm
r.asm
.org/
D
ow
nloaded from
 
of a 5-day regimen of either mupirocin or bacitracin for S. aureus
nasal decolonization in health care workers. It was shown that
after 30 days, bacitracin was inferior to mupirocin for eradication
of S. aureus (23% versus 80%; P 0.01) (77).
Bacitracin is also available in combination with polymyxin B
(polysporin) and/or neomycin (neosporin). Polymyxin B is de-
rived from Bacillus polymyxa. Polymyxins bind to the bacterial cell
membrane, which then leads to a modification of the structure.
This then creates a permeable cell wall and cell death. Neomycin is
an aminoglycoside which binds to the 30S ribosomal subunit and
interferes with protein synthesis. Both polymyxin and neomycin
have activity against most Gram-negative bacilli. Fung et al. used
polysporin ointment in a pilot study without a control group,
which evaluated patients who previously failed MRSA decoloni-
zation with mupirocin. Of the 11 study patients, nine became
decolonized, including three patients who had HL-MR (78).
However, in an RCT, investigators compared mupirocin with
polysporin triple ointment twice daily along with 2% CHG washes
for 7 days to eradicate MRSA colonization. At least half of the
patients in each group were colonized in multiple body sites (nasal
and extranasal). After 48 h, 65% of the mupirocin group and 31%
of the polysporin group were MRSA negative at every body site
(P 0.001). At 3 months, patients who received mupirocin were
more likely to remain MRSA free than those who received polys-
porin, but this did not reach statistical significance (P 0.22). The
authors concluded that although neither agent performed well,
polysporin was significantly less efficacious than mupirocin (79).
Rates of allergic dermatitis have also been found to be higher with
bacitracin and neomycin than with mupirocin, ranging from 8%
to15% (80). Given inferior outcomes and increased risk of allergic
dermatitis, the use of bacitracin-containing compounds cannot be
recommended as a decolonization strategy.
Retapamulin
Retapamulin belongs to a new antibiotic class called pleuromuti-
lins. Retapamulin acts against Gram-positive and Gram-negative
bacteria by interacting at the 50S subunit of the ribosome (81). It
is approved for treatment of impetigo due to Streptococcus pyo-
genes or MSSA because it is highly active against S. aureus and S.
pyogenes, with MIC90s of 0.12g/ml and 0.03g/ml, respectively.
It is also active against both MRSA and mupirocin-resistant staph-
ylococci (64).
Although this agent has not been approved by the U.S. Food
and Drug Administration (FDA) for nares application, a double-
blinded, placebo-controlled RCT of nasal retapamulin was re-
ported at an international conference in 2008. This RCT evaluated
43 patients to determine whether 3- and 5-day nasal applications
of retapamulin can eradicate persistent S. aureus nasal carriage.
Persistent carriers were defined as positive for S. aureuson all three
screening visits and immediately prior to the initial dose. Reta-
pamulin led to S. aureus nasal decolonization in 92% to 94% of
patients at 7 days and in 75% to 86% at 28 days. The most com-
mon adverse events included sneezing, nosebleed, and headache.
Both groups experienced similar rates of nasal discomfort and
rhinorrhea (82). There is currently a phase 4 study of nasal decolo-
nization with retapamulin versus placebo to eradicate LL-MR and
HL-MR MRSA nasal colonization in adults (https://clinicaltrials
.gov/ct2/show/NCT01461668). Additional studies are needed.
Povidone-Iodine
Povidone-iodine (PI) is a complex of polyvinylpyrrolidine and
tri-iodine ions that has been widely used as an antiseptic on skin,
wounds, and mucous membranes. PI has activity against both
Gram-positive and Gram-negative bacteria. Specifically, PI has
activity against both MSSA and MRSA. Hill and Casewell (83)
assessed the in vitro activity of 5% PI as an alternative to mupiro-
cin for the nasal decolonization of S. aureus. In that study, PI was
able to eliminate 11 test organisms, including both mupirocin-
sensitive and mupirocin-resistant MRSA; however, the addition
of nasal secretions in vitro reduced the PI activity. The results
suggested that PI may be a good decolonizing agent for the pre-
vention of infections due to S. aureus, including MRSA and mupi-
rocin-resistant strains.
Phillips et al. (84) performed a prospective, open-label trial of
twice-daily nasal mupirocin for 5 days before surgery compared to
two applications of a 5% nasal PI solution within 2 h of surgical
incision in patients undergoing arthroplasty or spine fusion sur-
gery. A nasal PI solution was used because it has a film-forming
substance which enables better adherence to nasal mucosa. Both
groups also received CHG baths, with 2% cloths used, the night
before and the morning of surgery. Phillips et al. evaluated 763
surgical procedures among patients who received mupirocin and
776 surgical procedures among patients who received PI. In the
per-protocol analysis, S. aureus deep SSIs developed in five pa-
tients (0.66%) who received mupirocin and zero patients (0.00%)
among those who received PI (P  0.03). In addition, if the pre-
operative nasal culture was positive for S. aureus, another nasal
culture was obtained within 1 to 3 days after surgery. The propor-
tion of postoperative negative nasal cultures was 92% (78 of 85
patients) for those assigned to mupirocin versus 54% (45 of 84
patients) for those assigned to PI. The authors commented that
this was not unexpected, since mupirocin was intended to eradi-
cate colonization while PI was intended only to suppress S. aureus
during surgery. This study has several limitations. First it was a
single-site study, and the results may not be generalizable. Second,
the authors could not perform multivariate analysis due to the
small sample size. Third, patients were not followed after dis-
charge to identify late infections (84).
Bebko and colleagues (85) recently published a preoperative
decontamination protocol to reduce SSIs in orthopedic patients
undergoing elective hardware implantations. This was a quasi-
experimental, retrospective, nonrandomized trial comparing a
bundled intervention to historical controls. The intervention con-
sisted of application of 2% CHG and oral CHG the night before
and morning of surgery plus an intranasal PI solution the morning
of surgery. Patients were evaluated for SSI for the 30 days after
their surgery date. Rates of SSIs were statistically significantly
lower in the intervention group than in the control group (1.1%
versus 3.8%; P 0.02). However, that study was limited because it
was not a randomized trial, patients were only followed for 30
days, and information regarding the MRSA carrier status of pa-
tients before and after decontamination was not collected; there-
fore, the study did not allow for evaluation of the effect of nasal
decolonization against other interventions. Nasal PI has not been
studied in other clinical settings. In conclusion, although nasal PI
may be a potential alternative to nasal mupirocin for prevention of
SSIs, more studies are needed.
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Alcohol-Based Nasal Antiseptic
Alcohol has bactericidal activity against most Gram-positive and
Gram-negative bacteria, including MDROs. Alcohol concentra-
tions between 60 and 90% are most effective. Alcohols are antimi-
crobial because they are able to denature proteins. Most alcohol-
based hand antiseptics contain either isopropanol or ethanol (86).
Steed et al. (87) recently published a double-blinded, placebo-
controlled RCT testing the effectiveness of an alcohol-based nasal
antiseptic in reducing S. aureus nasal colonization in colonized
health care workers. Health care workers testing positive for nasal
S. aureus colonization were treated three times during the day with
a nasal alcohol-based antiseptic or placebo. The antiseptic formu-
lation contained 70% ethanol combined with natural oil emol-
lients and the preservative benzalkonium chloride. Nasal S. aureus
and total bacterial colonization levels were determined before and
at the end of a 10-hour shift. Antiseptic treatment reduced S. au-
reus CFU from baseline by 82% (mean) and 99% (median) (P
0.001). A much larger study involving patients colonized with S.
aureus will be necessary to determine if decolonization with a
nasal ethanol antiseptic can reduce S. aureus infections.
INVESTIGATIONAL NASAL AGENTS
Tea Tree Oil
Tea tree oil is extracted from the Melaleuca alternifolia plant and
has broad-spectrum antimicrobial activity. In a pilot study of 30
patients, a combination of 4% tree oil nasal ointment with 5% tree
oil body wash was evaluated against 2% mupirocin nasal ointment
with triclosan body wash for MRSA decolonization at 48 to 96 h.
The tree oil treatment cleared MRSA in 5 of 15 patients (33%),
compared to 2 of 15 patients (13%) who received mupirocin with
triclosan. Fifty-three percent of patients who received mupirocin
with triclosan were still colonized when the treatment ended,
compared with 20% of patients who received tea tree oil. The
difference was not statistically significant, potentially due to the
small sample size (88).
In a larger trial, Dryden et al. (89) compared a tea tree oil regi-
men with nasal mupirocin ointment, CHG wash, and silver sulfa-
diazine among hospitalized patients. The tea tree oil regimen
comprised application of 10% tea tree cream to the anterior nares
three times a day for 5 days and a 5% body wash at least once a day
for 5 days plus 10% cream to skin lesions and open wounds. The
mupirocin regimen consisted of application of 2% nasal mupiro-
cin ointment to the anterior nares three times a day plus 4% CHG
soap over the entire body at least once per day plus 1% sulfadia-
zine cream to skin lesions and open wounds. Prior to treatment,
swabs were collected from each patient’s nose, throat, axilla, groin,
and any open lesions. These swabs were then tested for MRSA. The
same set of cultures was performed after treatment on days 2 and
14. Persistent MRSA colonization at any site was considered to be
decolonization failure. A total of 236 patients colonized with
MRSA were included in the study. There was no significant differ-
ence between the regimens at 14 days. Successful decolonization
occurred among 41% of the patients in the tea tree oil group and
49% of patients in the mupirocin treatment group. Interestingly,
mupirocin was more successful at decolonizing the nares (78%)
than tea tree cream (47%) (P  0.01), yet tea tree treatment was
more successful than CHG or silver sulfadiazine at decolonizing
the skin. Compliance with treatment regimens was not closely
monitored. There were no reports of adverse events. The authors
concluded that tea tree preparations may be an effective and safe
alternative to mupirocin-containing regimens in eradicating
MRSA carriage (89). The optimal concentration of tea tree oil for
decolonization is not known. Therefore, more studies are needed
to determine the optimal concentration to eradicate colonization
of S. aureus, to standardize that concentration, and to determine if
decolonization with tea tree oil can reduce S. aureus infections.
Photodynamic Therapy
The use of a light source, such as a laser, has been suggested as an
alternative method to eliminate MRSA nasal carriage. However,
studies have shown that laser use alone may not be capable of total
bacterial eradication (90). Photodynamic therapy (PDT) consists
of the combination of a light-activated chemical and UV or infra-
red wavelengths. This combination creates free radicals that dam-
age bacterial cell walls and membranes. One such chemical is
methylene blue, which, when activated by laser light energy, has
been shown to kill microbial cells. Embleton et al. demonstrated
that a monoclonal antibody conjugate targeting MRSA, when ex-
posed to red light, selectively eliminated MRSA in all growth
phases while not harming Escherichia coli and Staphylococcus epi-
dermidis. This suggested that PDT may protect normal human
flora while eliminating the target organism (91).
A second study used a bacteriophage conjugated with a photo-
sensitizer targeting S. aureus. In this study, more than a 3-log10 kill
was demonstrated, with little effect on human epithelial cells (92).
Street and colleagues (93) used a methylene blue- and CHG-based
photosensitizer formulation. That study evaluated the efficacy of
using PDT for nasal MRSA decolonization at the preclinical and
clinical levels. Preclinical testing was done in a custom nasal res-
ervoir model and on human skin cultures colonized with MRSA.
Human clinical testing was also performed. Using full-thickness
skin cultures, they performed photodynamic treatment compari-
sons with either methylene blue or CHG alone or the combination
of methylene blue and CHG. They found that the combination
formulation using both methylene blue and CHG was much more
effective than either methylene blue or CHG alone. Application of
methylene blue or CHG alone with illumination led to some re-
duction in MRSA viability compared with that for the control
(0.2-log10 and 1.1-log10 reductions, respectively) immediately
posttreatment. In contrast, PDT treatment using a combination of
methylene blue and CHG produced a statistically significant 5.1-
log10 reduction compared with the nontreated control and a rapid
antibacterial effect. In addition, the combination produced sus-
tained decolonization that persisted for up to 5 days (93).
In preliminary human testing, PDT eradicated nasal MRSA,
with total treatment times of less than 10 min (93). In a small
cohort study, Bryce et al. found that the colonization rates for
MSSA and MRSA were 24.4% and 0.9%, respectively, before PDT
therapy (94). Of those who received PDT (0.1% methylene blue
plus laser), 85% had a reduced S. aureus burden in the anterior
nares as measured by semiquantitative colony counts (95). In a
follow-up study, patients undergoing elective cardiac surgery, or-
thopedic surgery, spinal surgery, vascular surgery, thoracic sur-
gery, or neurosurgery were asked to bathe with 2% CHG cloths in
the 24 h prior to surgery and were given intranasal PDT (0.1%
methylene blue plus laser) in the preoperative area. There was a
statistically significant decrease in the SSI rate when comparing
treated patients to a historical control group (1.6% versus 2.7%;
P 0.0004; OR 1.73; 95% CI, 1.28 to 2.34). The intention-to-
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treat analysis also demonstrated that PDT was associated with a
decrease in rates of SSIs. Overall compliance was 94%. However,
the study was limited, since the benefits of CHG alone compared
to PDT alone were not evaluated (94).
Laser therapy for nasal decolonization could also potentiate an-
tibiotics that were previously ineffective. Bornstein et al. (96)
demonstrated the antibiotic-enhancing effect on MRSA with
erythromycin cream where erythromycin cream alone did not re-
duce MRSA. Laser therapy alone produced a 57% reduction in
MRSA, versus 97% when laser use was followed by application of
erythromycin cream. The authors discussed that one of the mech-
anisms for erythromycin-resistant S. aureus is the use of efflux
pumps to transport erythromycin out of the cell. However, inhib-
itors of ATP synthesis can stop these cellular transport systems.
They postulated that the inhibition of energy-dependent efflux
mechanisms by sublethal doses of 870-nm/930-nm laser energy
contributes to the potentiation of erythromycin against S. aureus.
In a pilot study, Krespi and Kizhner (97) published the first hu-
man study using laser therapy followed by topical erythromycin
cream. Among the 14 S. aureus-colonized patients who received
laser therapy followed by topical erythromycin cream, 13 became
decolonized. Decolonization was maintained at 4 weeks.
Photodynamic therapy is a promising approach for topical
MRSA decolonization, but larger clinical trials are needed to eval-
uate different nasal decolonization protocols (including deter-
mining the optimal sensitizer) using clinically significant infection
as the outcome.
Omiganan Pentahydrochloride
The investigational agent omiganan pentahydrochloride is a
unique topical peptide that has in vitro activity against Gram-
positive and Gram-negative bacteria and yeasts (98). The peptide
can depolarize membranes, leading to cell death. In a recent study,
omiganan was active against S. aureus, including strains that are
vancomycin intermediate and vancomycin resistant, even at levels
much lower than the clinical formulation (1% gel; 10,000 g/ml)
(99). In a separate study, omiganan was assessed against over
1,000 clinical bacterial isolates as well as 214 clinical yeast isolates.
Omiganan was found to be highly active against the bacterial and
yeast isolates, including MRSA (98). This agent appears to be
promising and merits further clinical studies.
Lysostaphin
The investigational agent lysostaphin is a glycylglycine endopep-
tidase that is active against staphylococci through cleavage of the
cross-linking pentaglycine bridges in staphylococcal cell walls.
One study evaluated the in vitro activity of lysostaphin against 429
isolates from human blood and nares and found that lysostaphin
was active against all 429 isolates, including MSSA and MRSA
(100). Kokai-Kun et al. found that lysostaphin was active against
all of isolates that they tested and rapidly lyses both growing and
stationary-phase S. aureus (101). They also found in a cotton rat
model that when they compared mupirocin to one application of
0.5% lysostaphin cream, the lysostaphin was more effective at
eradicating nasal MRSA, MSSA, and mupirocin-resistant S. au-
reus. In another study, the authors compared the activities of lys-
ostaphin, tea tree oil, and mupirocin against 98 MRSA clinical
isolates. Using 24-h time-kill studies, lysostaphin was more effec-
tive than either mupirocin or tea tree oil (102). Lysostaphin may
offer a therapeutic option, but results need to be validated by
well-designed RCTs.
TOPICAL AGENTS
Topical Chlorhexidine Gluconate
Chlorhexidine, a topical antiseptic, has been used throughout the
world for decades. Chlorhexidine gluconate (CHG) is a cationic
biguanide that works by binding to bacterial cell walls, which al-
ters the osmotic equilibrium of the bacterial cell. CHG has activity
against Gram-positive and Gram-negative bacteria and yeasts.
CHG has an excellent safety record. Adverse events associated
with CHG are mild skin irritation and rare serious allergic reac-
tions (103).
CHG efficacy has been documented for diverse indications, in-
cluding handwashing, procedure skin preparation, vaginal anti-
sepsis, oral care for prevention of ventilator-associated pneumo-
nia (VAP), gingivitis treatment, and body washes for infection
prevention. CHG is available in a wide range of concentrations
(0.5% to 4%) and formulations. CHG can be used on its own or
combined with ethanol or isopropyl alcohol. Some CHG products
are also sold over the counter. This review focuses only on the use
of CHG to prevent HAIs.
In 1991, a study demonstrated that CHG alcohol disinfection of
the central line site before insertion was associated with a signifi-
cant reduction in central-line-associated infections compared
with 10% PI or 70% alcohol (104). The use of CHG alcohol has
now become the standard of care for site preparation and main-
tenance (105).
Recently, multiple studies have evaluated the use of CHG bath-
ing to decrease the bacterial burden on the skin of ICU patients in
an effort to reduce HAIs. CHG bathing can decrease the biobur-
den of bacteria and yeasts on patients, the hospital environment,
and the hands of health care workers (106). Bleasdale et al. ob-
served a 60% reduction in bloodstream infections (BSIs) among
medical ICU patients who were bathed with 2% CHG cloths daily
compared with soap and water (107). Borer et al. examined the
association between 4% CHG liquid body wash use and multi-
drug-resistant Acinetobacter baumannii skin colonization and
BSIs in the medical ICU. Patients underwent CHG bathing imme-
diately after obtaining initial cultures. Seventeen percent of pat-
ents were colonized with Acinetobacter baumannii on admission,
5.5% at 24 h, and 1% at 48 h (P  0.002). The prevalence of
Acinetobacter baumannii BSIs decreased from 4.6 to 0.6 per 100
patients, and the incidence decreased from 7.6 to 1.25 (85% re-
duction) (108).
In the year 2013 alone, three randomized cluster trials on the
topic of CHG bathing among ICU patients were published. One
cluster-crossover study reported that daily 2% CHG cloth bathing
in the ICU resulted in a 23% reduction of VRE and MRSA acqui-
sition and a 28% reduction in BSIs (26). In another study of pe-
diatric ICU patients, Milstone et al. found a significant association
between 2% CHG cloth bathing and a decline in BSIs compared
with standard bathing (109). Another trial, called the REDUCE
MRSA study, cluster randomized 74 adult ICUs to evaluate three
MRSA prevention interventions: the first cluster imple-
mented MRSA screening and isolation, the second cluster in-
cluded screening, isolation, and decolonization of MRSA carriers
with CHG bathing and nasal mupirocin (i.e., targeted decoloniza-
tion), and the ICUs in the third cluster did not screen any patients
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but instead all patients decolonized with CHG cloth bathing and
nasal mupirocin (i.e., universal decolonization). Universal de-
colonization was found to be associated with the greatest decrease
in all-cause BSIs (44%; P  0.001) and rates of MRSA clinical
cultures (37%; P 0.01) (40). In a secondary analysis, CHG bath-
ing was also shown to reduce blood culture contamination by 45%
(P 0.02), confirming earlier studies (29).
In 2014, a European quasi-experimental study evaluated
whether universal CHG cloth bathing, in addition to improved
hand hygiene compliance, could decrease acquisition of MDROs.
That study found that this intervention was associated with a sig-
nificant decline in MDROs. Then, in a subsequent cluster ran-
domized trial, they found that the addition of rapid screening and
isolation did not lead to a further decline in MDROs (110).
In 2015, Noto et al. (111) published a cluster-randomized cross-
over study of five different ICUs in a single academic institution.
ICUs were randomized to bathing with either CHG or nonanti-
microbial cloths for 10 weeks, and then there was a 2-week wash-
out period, after which ICUs were crossed over to 10 weeks of the
other bathing treatment. The study evaluated a composite out-
come of CLABSIs, VAP, CAUTIs, and CDI. This study also eval-
uated MDRO clinical culture rates, blood culture contamination,
and health care-associated BSIs. Unlike in the previous trials,
CHG did not reduce the incidence of HAIs. The findings in this
study need to be interpreted in light of several limitations. For one,
the study did not monitor adherence to the bathing protocol, so it
is possible that the lack of benefit reflected inadequate bathing.
Second, two of five units were already using CHG. Third, the
intervention was only 10 weeks long. It takes a minimum of sev-
eral weeks to ramp up to ensure adequate training and compli-
ance; thus, many patients may not have received CHG bathing
during the intervention periods. Fourth, for two of the HAIs in the
composite outcome, VAP and CDI, one would not expect reduc-
tions due to the use of CHG. Fifth, the study was conducted at a
single center. Lastly, the baseline rates of hospital-acquired infec-
tions were low before the study was started, so it may not have
been statistically powered to see a difference (111).
A study of long-term acute-care hospital (LTACH) patients as-
sessed whether the use of daily 2% CHG bathing cloths was asso-
ciated with lower Klebsiella pneumoniae carbapenemase-produc-
ing Enterobacteriaceae (KPC) skin colonization. That study
reported that CHG bathing was associated with decreased KPC
skin colonization, especially when CHG skin concentrations were
greater than 128 g/ml. In the study, 35 (56%) of 62 patients had
at least one skin site positive for KPC immediately before bathing,
versus 20 (32%) of 62 patients after bathing (P 0.01) (112). That
study was followed by a stepped-wedge study of LTACHs to test
whether an intervention, which included screening for KPC rectal
colonization, contact precautions, and daily CHG bathing, would
reduce KPC colonization and infection. It was concluded that the
intervention was associated with reductions in KPC colonization,
blood culture contamination, and BSIs due to all causes (113).
Cassir and colleagues recently published a single-center study
alternating soap and water bathing with CHG cloths in two di-
vided 6-month periods in the ICU (114). Twenty-nine patients in
the CHG group developed HAIs, versus 56 patients in the control
group (P  0.01). There were also statistically significant differ-
ences in the incidence of community-acquired BSIs, health
care-associated VAP, and health care-associated urinary tract in-
fections (UTIs). This effect was greater for HAIs due to Gram-
negative organisms. This result may be explained since the authors
enrolled only patients who already had a least one episode of sus-
pected sepsis. However, it is unclear how CHG bathing reduced
rates of community-acquired BSIs. Huang et al. also demon-
strated a 26% reduction in BSIs due to Gram-negative bacteria in
the universal decolonization arm of the REDUCE MRSA trial
(40). The studies by both Climo et al. and Huang et al. also showed
reduced infections due to Candida species (26, 40). Further large-
scale studies are needed to confirm this result.
Rupp et al. (115) evaluated the effectiveness of hospital-wide
CHG patient bathing on rates of HAIs. CHG bathing or showers
were given 3 days per week or daily. They reported a significant
decrease in infections due to CDI during the intervention period
and a statistically significant increase during the washout period.
Specifically, the decrease in CDI was statistically significant for
both CHG bathing 3 days per week (RR  0.71; 95% CI, 0.29 to
0.59; P 0.001) and for daily CHG bathing (RR 0.41; 95% CI,
0.29 to 0.59; P  0.001). The reduction in CDI was unexpected.
The authors speculated on some reasons but concluded further
studies were needed to validate their observation.
Lastly, appropriate CHG application requires adequate educa-
tion, training, monitoring, and feedback. Edmiston et al. showed
that mean residual CHG concentrations on the skin were much
higher in patients given instructions for showering with 4% CHG
soap compared with bathing without instructions (116). Finally
using a colorimetric assay to determine the CHG on skin, investi-
gators found that CHG application was suboptimal. An interven-
tion which included reeducation and feedback to nurses signifi-
cantly improved the percentage of skin sites positive for CHG
(117).
In summary, with the exception of the study by Noto et al.
(111), there is now a body of evidence that in settings of endemic-
ity, horizontal approaches that include universal decolonization
with CHG bathing and potentially nasal mupirocin may be more
effective than vertical strategies that include active surveillance
testing and isolation. These studies support the recently published
recommendation that ICU patients over 2 months of age should
be bathed with CHG on a daily basis to prevent CLABSIs as basic
practice (103). Although the incidence of CHG resistance is cur-
rently low and of uncertain clinical significance, resistance to
CHG should be monitored with more widespread use.
Hexachlorophane
Hexachlorophane has activity against Gram-positive bacteria but
is not effective against Gram-negative bacteria and anaerobes.
Hexachlorophane inhibits the electron transport chain of bacteria
(118). It is bacteriostatic in the standard 3% liquid concentration
and can take multiple days for an effective concentration to be
established on the skin. Hexachlorophane is contraindicated for
use in neonates because of systemic absorption that may lead to
neurotoxicity (119). Given its spectrum and toxicity, hexachloro-
phane is less clinically useful than CHG and therefore cannot be
recommended at this time.
Povidone-Iodine
Povidone-iodine has broad activity against both Gram-positive
and Gram-negative bacteria. Povidone-iodine is applied topically
in concentrations from 4% to 10%. It is well tolerated; however, it
may cause mild skin irritations. Povidone-iodine has a more rapid
bactericidal effect than CHG, but povidone-iodine has not been
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shown to have a persistent effect like CHG (120). One study com-
pared a CHG preparation to a povidone-iodine preparation for
surgical scrub use. The authors found that CHG had more persis-
tent activity than povidone-iodine (121). CHG is recommended
over 10% iodine solutions for catheter placement because CHG is
associated with a lower risk of infection (122). Although povi-
done-iodine has broad-spectrum properties, it is not ideal for top-
ical decolonization due to a lack of evidence for persistence and
inferior outcomes compared with CHG.
Triclosan
Triclosan has activity against both Gram-positive and Gram-neg-
ative bacteria. Triclosan works by targeting many intracellular
sites of bacteria. Triclosan resistance develops through a one-step
change in enoyl reductase (123). Triclosan is in many liquid soaps,
toothpaste, and acne preparations that can be purchased over the
counter. These range in concentrations from 0.15% to 1%. How-
ever, triclosan has been found in human urine, blood, and breast
milk as well as throughout the environment. The U.S. FDA and
the U.S. Environmental Protection Agency (EPA) are currently
performing scientific and regulatory reviews of the safety of tri-
closan (124). Giuliano and Rybak recently reviewed the evidence
evaluating the use triclosan as an antimicrobial soap and its asso-
ciation with antimicrobial resistance. They concluded that there
was no beneficial effect of triclosan over nonantimicrobial soap,
and triclosan resistance has been demonstrated. They concluded
that the risks outweighs the benefits of triclosan use (124).
Sodium Hypochlorite (Bleach)
Sodium hypochlorite alters cellular metabolism and causes phos-
pholipid destruction. Sodium hypochlorite has been used primar-
ily as part of MRSA decolonization. A recent trial compared no
intervention to one of three 5-day interventions: intranasal mupi-
rocin alone, intranasal mupirocin with daily CHG bathing, or in-
tranasal mupirocin plus daily bathing with dilute bleach (a quarter
cup of 6% sodium hypochlorite per tub of water). At 1 month, S.
aureus eradication occurred in only 38% of the control group
versus 56% with mupirocin alone (P  0.03), 55% in the mupi-
rocin and CHG group (P 0.05), and 63% in the mupirocin and
bleach group (P 0.01) (125). The most recent IDSA guideline on
MRSA recommends that children and adults who have recurrent
MRSA skin and soft tissue infections should use intranasal mupi-
rocin and bathe with bleach made with one-fourth cup of bleach
in a one-quarter tub (approximately 13 gallons), which represents
2.5 l/ml. These baths should last for 15 min and be performed
twice weekly over the course of 3 months (126).
Oral Care
To date, the only large, well-controlled clinical trials of oral care
interventions in at-risk patients involve the use of chlorhexidine.
Oral care with CHG is now standard practice for the prevention of
VAP; however, recent systematic literature reviews and meta-
analyses indicate limitations of the current evidence. Studies in-
volving cardiac surgery patients reveal the most compelling data,
where reductions in VAP rates, mortality, and length of stay have
been realized through the use of chlorhexidine (127, 128). Reports
vary on the potential impact of chlorhexidine use in other patient
populations. When tested in intensive care populations outside
cardiac surgery, chlorhexidine did not achieve the same positive
outcomes in in regard to mortality and decreased length of stay
(129, 130), although evidence around possible decreases in VAP
rates among severely ill patients intubated for more than 1 day is
growing (131, 132). Finally Klompas et al. published an article on
the reappraisal of routine oral care with CHG (133). They pointed
out that previous meta-analyses may be misleading because they
fail to distinguish cardiac surgery and noncardiac surgery. They
found that cardiac surgery patients who were randomized to re-
ceive CHG experienced fewer respiratory tract infections (RR 
0.56; 95% CI, 0.41 to 0.77), yet there was not a significant differ-
ence in risk of VAP among RCTs of non-cardiac surgery patients
(RR  0.88; 95% CI, 0.25 to 2.14). They concluded that routine
oral care with CHG prevents health care-associated pneumonia
only among cardiac surgery patients and not in non-cardiac sur-
gery patients. They admitted that their findings are not conclusive
and that large, adequately powered randomized trials are neces-
sary, especially with non-cardiac surgery patients.
ORAL AGENTS
Systemic antibiotics are usually unable to attain adequate concen-
trations in secretions to eradicate nasal S. aureus. Therefore, de-
colonization regimens may use a combination of oral antibiotics
with topical therapies. Oral therapy may be particularly useful for
patients colonized at multiples sites or extranasal sites.
A double-blinded RCT of 94 patients over 7 days evaluated
whether rifampin (300 mg twice daily) and novobiocin (500 mg
twice daily) combined or rifampin (300 mg twice daily) and trim-
ethoprim (160 mg)-sulfamethoxazole (800 mg twice daily) com-
bined decreased whole-body S. aureus colonization (134). It
found that 67% (30 of 45 patients) of the rifampin and novobiocin
group and 53% (26 of 49 patients) of the rifampin and trim-
ethoprim-sulfamethoxazole group were decolonized. Risk factors
for unsuccessful decolonization were found to be older age,
MRSA-positive wound culture, and greater than one colonized
site. An open-label RCT of hospitalized patients assessed a 7-day
regimen of 2% CHG bathing once daily, 2% intranasal mupirocin
used three times daily, 300 mg of oral rifampin twice daily, and 100
mg of doxycycline given twice daily compared with no treatment
for MRSA decolonization at all body sites (135). Of the 146 pa-
tients who were randomized, 112 patients were evaluated at 3
months. At 3 months, 74% (64 of 87 patients) of the treatment
group and 32% (8 of 25 patients) of the control group had nega-
tive MRSA cultures (RR 1.55; 95% CI, 1.17 to 2.04; P 0.01).
However, adverse events occurred in a quarter of the patients,
including nausea, vomiting, and diarrhea. Cluzet et al. recently
published a study to evaluate both colonization duration and
predictors of clearance of MRSA colonization. They found that
treatment of skin and soft tissue infection with clindamycin was
associated with earlier clearance of MRSA colonization (136). Al-
though the use of oral agents in decolonization of patients with S.
aureus has been evaluated in several studies, the optimal dose and
duration of therapy are still unclear, as well as whether combina-
tion therapy is preferred over monotherapy. Rifampin, quino-
lones, trimethoprim-sulfamethoxazole, novobiocin, clindamycin,
doxycycline, and minocycline have all been evaluated as oral de-
colonizing agents, but current data have not demonstrated a pre-
ferred agent (134, 137). In addition, it is unclear whether oral
agents are more efficacious than topical decolonizing agents. The
risk of resistance and side effects must be taken into consideration
when evaluating these therapies. Current guidelines recommend
against routine use of oral agents for decolonization (126).
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SELECTIVE DIGESTIVE OR OROPHARYNGEAL
DECONTAMINATION
Decontaminations of the upper respiratory and digestive tracts are
interventions designed to decrease colonization with pathogenic
Gram-negative organisms and infections in critically ill patients.
These interventions include selective digestive decontamination
(SDD) and selective oropharyngeal decontamination (SOD).
SDD is performed by application of nonabsorbable antibiotics to
the oropharynx and digestive tract. These nonabsorbable antibi-
otics include tobramycin, polymyxin, and amphotericin, as well as
a short course of intravenous antibiotics such as cefotaxime. Oro-
pharyngeal antibiotics are administered as a paste, while the gas-
tric antibiotics are administered as a suspension down the naso-
gastric tube. SOD consists of the application of topical antibiotics
to the oropharynx alone, and intravenous antibiotics are not
given. CHG is sometimes used in the approach (see above). Re-
ported effects on patient outcomes have been conflicting.
D’Amico and colleagues (138) performed a meta-analysis of
RCTs from 1984 to 1996. They evaluated two categories of trials.
The first consisted of those that assessed topical and systemic an-
tibiotics against a control group with no treatment. The second
category of trials assessed topical antibiotics with or without sys-
temic antibiotics against either systemic antibiotics or a placebo.
They concluded that the combination antibiotic prophylaxis with
both topical and systemic antibiotics was associated with a de-
crease in respiratory tract infections and mortality among criti-
cally ill patients. A 2007 meta-analysis evaluated the association
between oral decontamination and the incidence of VAP (139). It
included 11 trials totaling 3,242 mechanically ventilated patients
treated with oral application of either antibiotics or antiseptics or
standard oral care. When the study results were pooled, it was
found that both methods of oral decontamination were associated
with decreased risk of VAP (RR  0.61; 95% CI, 0.45 to 0.82);
however, significant differences for duration of mechanical venti-
lation, ICU length of stay, or mortality were not seen. In 2009, a
cluster randomized crossover study was performed in 13 ICUs
located in the Netherlands to evaluate the effectiveness of SDD
and SOD (140). Each ICU was randomized to implementation of
SDD, SOD, and standard care in a random order over a 6-month
period. In a logistic regression model, the SOD and SDD groups
had lower odds of death at 28 days than the group that received
standard care (SOD: OR 0.86; 95% CI, 0.740 to 0.99; and SDD:
OR  0.83; 95% CI, 0.72 to 0.97). For patients receiving SDD or
SOD, ICU bloodstream infections were statistically significantly
lower for S. aureus and nonfermenting Gram-negative organisms,
especially Pseudomonas aeruginosa and Enterobacteriaceae, than
with standard care. There was also a reduction in the number of
rectal swabs positive for Gram-negative bacteria among patients
who received SDD and in the number of oropharyngeal swabs in
both the SDD and SOD groups (140). In a follow-up study (11),
the investigators looked at the ecological effects of SDD and SOD.
During SDD, the average proportion of patients who were intes-
tinally colonized with Gram-negative bacteria resistant to ceftazi-
dime was 5%, that for tobramycin was 7%, and that for ciprofloxa-
cin was 7%, and this increased significantly to 15%, 13%, and
13%, respectively, postintervention (P  0.05). For organisms
resistant to ceftazidime, 39.9% were Enterobacter cloacae and
26.2% were Escherichia coli. For organisms resistant to ciprofloxa-
cin and tobramycin, most were E. coli: 50% for ciprofloxacin and
48.2% for tobramycin. When SDD and SOD were implemented,
the proportion of respiratory tract isolates that were resistant to all
three antibiotics was less than 7%. However, that proportion of
isolates that were resistant gradually increased during the inter-
vention to 10% or more for ceftazidime, tobramycin, and cipro-
floxacin in the postintervention period. For organisms resistant to
ceftazidime, 38.2% consisted of Enterobacter cloacae and 33.6% of
Pseudomonas aeruginosa. For organisms resistant to ciprofloxacin
and tobramycin, most were P. aeruginosa: 49.6% for ciprofloxacin
and 43.5% for tobramycin (11).
In another follow-up study (141), SOD and SDD were also
associated with decreased rates of bacteremia and colonization of
the respiratory tract with antibiotic-resistant Gram-negative bac-
teria among patients admitted to the ICU for greater than 3 days.
That study included 47 episodes of acquired BSI that were caused
by highly resistant organisms. BSIs acquired in ICUs and caused
by highly resistant pathogens were 59% less frequent with SDD
than with standard care and 63% less frequent with SDD than with
SOD. In a later large trial also in the Netherlands (142), the au-
thors compared SDD to SOD in regard to antibiotic resistance and
patient outcomes. They reported that both SDD and SOD were
associated with low levels of antibiotic resistance and that there
was no difference in 28-day mortality. Compared with SOD, SDD
was associated with decreased rates of BSIs acquired in the ICU
and rectal colonization of multidrug-resistant Gram-negative or-
ganisms. However, SDD was also associated with an increase in
aminoglycoside-resistant Gram-negative organisms. The reduc-
tion in BSIs was more pronounced for Enterobacteriaceae (OR 
0.42; 95% CI, 0.29 to 0.60), including aminoglycoside-resistant
Gram-negative pathogens (OR 0.54; 95% CI, 0.31 to 0.97).
Price et al. (143) published a systematic review and meta-anal-
ysis evaluating SDD, SOD, and topical CHG compared to stan-
dard care or placebo to determine the association with mortality
in adult patients in general ICUs. SDD was protective against mor-
tality, with a pooled OR of 0.73 (95% CI, 0.64 to 0.84). SOD was
also associated with decreased mortality with a pooled OR of 0.895
(95% CI, 0.74 to 0.97). CHG was actually associated with higher
mortality (OR 1.25; 95% CI, 1.05 to 1.5). About half of patients
in this analysis were ventilated ICU patients from the Netherlands.
There remains concern that SDD or SOD may result in selection of
resistant organisms. Daneman et al. (144) published a systematic
review and meta-analysis on the effect of select decontamination
on antimicrobial resistance. They were unable to detect an associ-
ation between SDD or SOD and antimicrobial resistance in ICU
patients. However, they did admit that the association between
decolonization and antimicrobial resistance in the ICU setting
needs more research.
Several recent studies have examined the role of SDD in reduc-
ing colonization, infections, and outbreaks caused by multidrug-
resistant Gram-negative bacteria. Huttner et al. (145) performed a
double-blinded, placebo-controlled RCT to evaluate the efficacy
of oral colistin, neomycin, and nitrofurantoin to reduce intestinal
colonization with ESBL-producing Enterobacteriaceae. This regi-
men temporarily suppressed ESBL-producing Enterobacteriaceae
during and immediately after treatment, but the authors docu-
mented a rebound only 1 week after ending treatment.
Saidel-Odes et al. (146) performed a blinded RCT comparing pla-
cebo to oral gentamicin and oral polymyxin gel plus oral solutions of
gentamicin and polymyxin for 7 days to eradicate carbapenem-resis-
tant Klebsiella pneumoniae (CRKP) oropharyngeal and gastrointes-
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tinal carriage. After 2 weeks, the proportion of rectal cultures that
were negative for CRKP was significantly improved in the interven-
tion group (16% in the placebo group versus 61% in the intervention
group [OR 0.13; 95% CI, 0.02 to 0.74; P 0.0016]). A difference
was still maintained at 6 weeks (33.3% in the placebo arm and 58.5%
in the intervention arm), but it was not statistically significant. Sec-
ondary resistance to gentamicin or colistin was not observed in any of
the SDD-treated patients. In another study (147), nonabsorbable oral
antibiotics were administered for up to 60 days or until decoloniza-
tion was documented in patients colonized with CRE. Oral gentami-
cin or oral colistin was used based on the susceptibility of the isolate.
Patients with isolates sensitive to both colistin and gentamicin were
randomized to receive either colistin or gentamicin or both. Patients
with isolates resistant to both agents were not provided with SDD but
were followed to document spontaneous clearance of CRE. Eradica-
tion rates in the three treatment groups (gentamicin, colistin, or
both) were 42%, 50%, and 37.5%, respectively, each significantly
higher than the 7% spontaneous clearance in the control group (P
0.001,P0.001, andP0.004, respectively). However, there was no
significant difference between the three treatment groups. Mortality
in patients who achieved eradication (either spontaneously or by
SDD) was significantly lower than that in patients where eradication
failed (17% versus 49%, respectively; P  0.002). Secondary resis-
tance developed in 7 of the 50 SDD-treated patients, gentamicin re-
sistance in 6 of 26 gentamicin-treated patients, and colistin resistance
in 1 of 16 colistin-treated patients (147).
In summary, despite a large number of favorable studies in this
area, clinicians are still unclear on the appropriate use of SDD and
SOD. Based on studies performed in ICUs that had low levels of
antibiotic resistance, SDD or SOD most likely does not result in in-
creased resistance in Gram-negative bacteria. However, the use of
SDD where resistant Gram-negative bacteria may be endemic has
resulted in conflicting results. Therefore, in settings where resistant
Gram-negative bacteria are endemic, SDD should be used only with
careful microbiological monitoring for development of resistance.
Larger studies that include longitudinal investigation of selection for
drug resistance and other poor outcomes are needed to determine the
optimal use of SDD or SOD, especially in health care settings where
antimicrobial resistance is endemic.
Other interesting investigational decolonizing agents that need
more study include bacteriophages, fecal microbiota transplant,
and probiotics (76, 148). Clinical trials should be performed to
investigate these agents.
DECOLONIZATION PRIOR TO SURGERY
The strongest evidence supporting decolonization is among sur-
gical patients. More studies have evaluated decolonization among
surgical patients than among any other patient population (38, 42,
44). Studies have shown that decolonization can decrease the in-
cidence of Gram-positive SSIs after some types of surgery (38,
149). This is because SSIs are often endogenous, spreading from
one body site (e.g., nose or skin) to the surgical wound of the same
patient. Multiple studies have demonstrated that the genotypes
(determined via PFGE) of S. aureus colonizing and infecting iso-
lates are identical in 75% to 85% of surgical patients (56, 149).
There is strong evidence that nasal and skin decolonization
prior to cardiac and orthopedic surgery is effective at preventing
SSIs caused by Gram-positive organisms that are susceptible to
mupirocin and CHG. A meta-analysis of 17 RCTs or quasi-exper-
imental studies that included cardiac and orthopedic surgery pa-
tients evaluated the effectiveness of preoperative decolonization
(38). All but one of the studies included in the meta-analysis used
mupirocin ointment for nasal decolonization, but one study used
nasal CHG (150). The meta-analysis found that decolonization
was significantly protective against Gram-positive SSIs, specifi-
cally S. aureus SSIs (Table 3).
Decolonization was protective against SSIs when the site of de-
colonization was the nares alone and when both the nares and the
skin were decolonized. Additionally, decolonization was found to be
effective against both MRSA and MSSA SSIs. One of the larger RCTs
included in that meta-analysis was performed in the Netherlands,
which experiences very little MRSA (149). That study used PCR to
rapidly identify S. aureus carriers and randomized 918 carriers to
either placebo or nasal mupirocin and CHG soap. It found a greater-
than-2-fold decline in S. aureus infections and more than a 4-fold
decline in S. aureus deep SSIs. Another large, quasi-experimental
study included in the meta-analysis prospectively evaluated 992 con-
secutive open heart surgery patients who did not receive mupirocin
prophylaxis in the 22-month preintervention period. They then be-
gan providing open heart surgery patients with intranasal mupirocin
and CHG bathing on the night before and morning of surgery, as well
as mupirocin twice daily for 5 days postoperatively. This intervention
group of 854 consecutive patients was followed prospectively for the
16-month intervention period. The rate of sternal wound infections
decreased significantly from 2.7% (27 of 992) in the preintervention
group to 0.9% (8 of 854) in the intervention group (P0.005) (151).
Studies that found a protective effect against SSIs used nasal
mupirocin twice daily for 3 to 5 days prior to surgery and CHG
bathing once daily for 2 to 5 days prior to surgery (56, 152, 153). If
a patient was unable to complete the decolonization regimen be-
fore surgery, the studies also recommended continuing nasal de-
colonization during the postoperative period but discontinuing
the CHG postoperatively (152, 153).
A recent pragmatic quasi-experimental study implemented a
bundled intervention in 20 hospitals in order to prevent complex S.
aureus SSIs after cardiac surgery and hip and knee arthroplasty (152).
TABLE 3 Pooled relative risks evaluating the protective effect of decolonization among studies that evaluated cardiac operations and total joint
arthroplastiesa
SSI type
Pooled relative risk (95% CI)
All studies Cardiac studies
Total joint arthroplasty or
orthopedic studies
Gram positive 0.41 (0.30–0.55) 0.46 (0.32–0.67) 0.32 (0.22–0.47)
S. aureus 0.39 (0.31–0.50) 0.45 (0.34–0.58) 0.32 (0.21–0.47)
MRSA 0.30 (0.15–0.62) 0.69 (0.36–1.31) 0.16 (0.09–0.28)
MSSA 0.50 (0.37–0.69) 0.46 (0.29–0.72) 0.56 (0.31–1.01)
a Adapted from reference 38 by permission from BMJ Publishing Group Limited.
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The bundle included CHG bathing for all patients, screening for
MRSA and MSSA nasal colonization, nasal mupirocin decoloniza-
tion for S. aureus carriers, and both vancomycin and cefazolin peri-
operative prophylaxis for MRSA carriers. The mean rate of complex
S. aureus SSIs significantly decreased from 36 infections per 10,000
operations during the baseline period to 21 infections per 10,000 op-
erations during the intervention period (rate ratio  0.58; 95% CI,
0.37 to 0.92). This significant decline was also seen when the study
was limited to only patients undergoing hip and knee arthroplasty
(rate ratio  0.48; 95% CI, 0.29 to 0.80), but it was not statistically
significant when the study was limited to only patients undergoing
cardiac surgery (rate ratio0.86; 95% CI, 0.47 to 1.57). However, the
number of cardiac surgery patients was much smaller than the num-
ber of orthopedic surgery patients, so the cardiac analysis may have
been underpowered.
A study performed in Ireland evaluated whether cardiac surgery
should be delayed until MRSA-colonized patients were fully decolo-
nized (154). In this study, elective surgery patients were screened for
MRSA colonization in the preoperative clinic, and if they were posi-
tive, the surgery was delayed until a decolonization regimen was com-
pleted. Urgent surgery patients were screened for MRSA when they
were admitted to the hospital, but their surgery was not delayed.
Rather, the decolonization regimen was implemented for MRSA-col-
onized patients postoperatively. This study found that the decoloni-
zation regimen was associated with fewer MRSA infections among
patients who received preoperative decolonization. The authors rec-
ommended that when clinical urgency permits, surgery should be
delayed in order to implement the decolonization regimen, particu-
larly prior to operations that include implantation of prosthetic ma-
terial (e.g., valve replacement) or among diabetic patients. However,
they also concluded that they do not support risking cardiac death by
delaying urgent surgery.
A meta-analysis by Kallen et al. aimed to determine whether
intranasal mupirocin decolonization could prevent SSIs caused by
any pathogen (42). They categorized surgery into nongeneral
surgery and general surgery. They hypothesized that general
surgical procedures, especially those that involve the bowel,
would be more likely to be associated with SSIs caused by or-
ganisms that are not susceptible to mupirocin (e.g., Gram-
negative or anaerobic organisms), and thus attenuate the effect
of mupirocin. Mupirocin use among non-general surgery pa-
tients (e.g., those undergoing cardiothoracic surgery, neuro-
surgery, or orthopedic surgery) was associated with a reduction
in SSIs. Conversely, mupirocin use among general surgery pa-
tients (e.g., those undergoing gastrointestinal, oncologic, or
gynecologic surgery) did not reduce SSIs. Thus, mupirocin de-
colonization is recommended for clean nongeneral procedures
but not for general surgical procedures that are associated with
contamination from the gastrointestinal tract during the oper-
ation. The recent Society for Healthcare Epidemiology of
America compendium of strategies to prevent SSIs stated that
screening for S. aureus and decolonization with agents such as
mupirocin could be done as a special approach when basic ap-
proaches are not enough, especially among patients undergoing
some orthopedic and cardiothoracic procedures (155).
ECONOMIC VIABILITY
Currently, evaluations of the cost-effectiveness of horizontal and
vertical decolonization interventions have been limited. A series of
economic computer models found that screening and nasal de-
colonization are cost-effective in some patient populations but
not others. Murthy et al. (156) evaluated a bundled intervention
that included PCR screening for MRSA prior to surgery, decolo-
nization of patients positive for MRSA with mupirocin and CHG,
and contact isolation for MRSA-positive patients. They found that
this was not strongly cost-effective, meaning that the costs avoided
through reducing MRSA infections did not offset the costs of
screening. However, this model was based on data from a hospital
in Geneva, which may have lower rates of MRSA colonization
than U.S. hospitals. Conversely, using data inputs from the United
States, multiple studies found that MRSA screening and decolo-
nization prior to cardiac, vascular, or orthopedic surgery or heart-
lung transplant was cost-effective from the third-party payer per-
spective and the hospital perspective (50, 157–161). However, Lee
et al., found that screening and decolonization of pregnant
women prior to cesarean delivery were not cost-effective (162).
Additionally, other economic models have found MRSA
screening and decolonization to be cost-effective among hemodi-
alysis patients, ICU patients, and all hospitalized patients (163–
167). Two different studies performed cost analyses of universal
decolonization in the ICU setting and found it to be cost-effective
(167, 168). One economic model compared seven different strat-
egies to prevent MRSA transmission and infection in ICUs and
found that the strategies that included decolonization were less
expensive and more effective than other strategies (165).
UNIVERSAL DECOLONIZATION VERSUS TARGETED
DECOLONIZATION
Currently, there is debate as to whether decolonization regimens
should be performed only among patients who are colonized with
pathogens that are sensitive to the decolonizing agents (e.g., S.
aureus) or whether all high-risk patients should receive decoloniz-
ing agents without being screened for colonization. Universal de-
colonization, i.e., decolonizing all high-risk patients regardless of
colonization status, requires health care workers only to provide
the decolonizing agents to the patients without the labor of
screening. Targeted decolonization requires the collection of a
screening swab and laboratory testing before decolonization. This
usually entails nasal screening for S. aureus colonization. Targeted
decolonization is considered by some to be the preferred standard
because antimicrobial agents would be used only in patients who
need them, which may prevent antimicrobial resistance. However,
this strategy would not identify patients who are S. aureus colo-
nized at extranasal body sites, would not decolonize patients with
false-negative results, and would not decolonize patients who are
colonized with other pathogens such as Gram-negative organ-
isms, yeasts, and the skin commensal organism CNS.
Depending on the patient populations, different laboratory
tests may be appropriate for screening. If fast results are needed,
real-time PCR can be used to test nasal swabs for both MRSA and
MSSA within 1 h (169). However, PCR is more costly than both
chromogenic agar (test time is at least 1 to 2 days) (170) and
standard culture (test time is approximately 2 to 3 days) (171).
Fast results may be needed in the preoperative clinic so that pa-
tients can be sent home with mupirocin and CHG as needed and
these decolonizing agents can be used prior to surgery. Slower
methods could be used for other patient populations who have
frequent contact with the health care system and longer periods of
time at risk and thus could obtain their decolonizing agents at
their next health care visit (e.g., dialysis patients). However, any
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type of screening is likely to be more expensive and certainly uti-
lizes more health care worker time than universal decolonization
(160, 161, 165).
Meta-analyses of decolonization studies among surgical and
nonsurgical populations found that universal and targeted de-
colonization strategies resulted in similar protection against S.
aureus infections (38, 44). The only multicenter study that com-
pared universal and targeted decolonization head-to-head found
that in the ICU, universal decolonization was more successful
than targeted decolonization at reducing the number of BSIs
caused by any pathogen, including Gram-positive skin commen-
sal organisms, Gram-positive noncommensal organisms, Gram-
negative organisms, and Candida species. There was not a signif-
icant difference in the reduction of MRSA BSIs between the
universal and targeted decolonization groups; however, there was
a trend toward a larger reduction among the universal decoloni-
zation group (40). Similarly, a study that evaluated universal CHG
bathing in ICUs found that universal decolonization led to a de-
cline in both VRE and MRSA acquisition and BSIs caused by any
pathogen (e.g., staphylococci, enterococci, Gram-negative bacilli,
and fungi) (26). Thus, universal decolonization is effective at re-
ducing the total number of positive cultures, including those that
may be due to contamination.
Universal decolonization can dilute the effects of the decoloni-
zation regimen. One RCT screened patients preoperatively for S.
aureus nasal carriage but then nasally treated all patients with
mupirocin or placebo before the nasal culture results were known.
That study did not show a significant decline in overall infections
after surgery but did show a significant decline in infections
among those who were S. aureus colonized (56).
The patient population must also be factored into the decision of
targeted versus universal decolonization. Universal decolonization
may be preferred in ICU settings, in which there is concern over both
endogenous infection and exogenous patient-to-patient transmis-
sion. In the ICU setting, missed colonization sites or false-negative
tests could result in the spread of pathogens from one patient to an-
other. Conversely, targeted decolonization may be preferred for pre-
operative and dialysis settings, where endogenous infections are the
main concern. There are even differences in the preoperative setting.
Targeted decolonization may be feasible for elective procedures but
not for urgent procedures such as emergency coronary artery bypass
graft. A compromise between the two types of decolonization prior to
surgery would be to attempt targeted decolonization with the knowl-
edge that some patients will be missed (e.g., those undergoing urgent
or emergent procedures). Then, if a patient presented to surgery with
unknown results, an informed decision could be made based on col-
onization rates in the community or in that surgical population to
determine whether that patient could be treated as colonized. Those
patients could receive a dose of mupirocin and a CHG bath prior to
surgery and finish the 3 to 5 days of mupirocin after surgery (153).
The primary concern regarding universal decolonization is the
emergence of resistance to the decolonizing agents. Most studies
of short-term use have not seen significant emergence of mupiro-
cin or CHG resistance (172). However, increased use of decolo-
nizing agents could lead to selection for resistant strains. One
study found that patients with persistent S. aureus carriage after
decolonization were statistically more likely to be S. aureus colo-
nized with isolates with combined LL-MR and chlorhexidine re-
sistance before decolonization than patients who were successfully
decolonized (173). Another study showed that decolonization
with chlorhexidine in the ICU led to selection of a nonepidemic
MRSA strain (ST239) that had reduced susceptibilities to chlo-
rhexidine (174).
There is also the concern that providing mupirocin and CHG to
patients who are not colonized with S. aureus could lead to selection
for other pathogens with resistance genes against those agents. Al-
though there have been only a few isolated examples in which the use
of these antimicrobials has promoted the spread of extremely drug-
resistant organisms (e.g., extremely drug-resistant strains of Kleb-
siella pneumoniae classified as ST258), this is still cause for concern
(175). Additionally, the resistance genes in other pathogens (e.g.,
CNS) could horizontally transfer from those pathogens to S. aureus
at a later time, leading to resistance in S. aureus (176).
CONCLUSIONS
In summary, colonization with health care-associated pathogens
such as S. aureus, enterococci, Gram-negative organisms, and C.
difficile is associated with increased risk of infection (28). The ma-
jority of these health care-associated infections may be prevent-
able by evidence-based interventions. Based on the evidence de-
scribed here, decolonization is one such intervention that can
reduce rates of health care-associated infections.
Decolonization prevents both vertical and horizontal transmis-
sion, depending on the method. There are several decolonization
methods, such as nasal, topical, and oral decontamination, with
many different products (Fig. 1). Mupirocin still remains the gold
standard agent for nasal decolonization of S. aureus, but there is
concern about mupirocin resistance, and alternative agents are
needed. The most promising new agents for nasal decolonization
are retapamulin, povidone-iodine, and alcohol-based nasal anti-
septics.
Chlorhexidine gluconate (CHG) is the skin decolonization
agent that has the strongest evidence base. CHG skin decoloniza-
tion is an effective horizontal strategy to reduce both the biobur-
FIG 1 Recognized decolonization strategies to prevent health care-associated
infections.
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den on the skin and subsequent infection. However, with wide-
spread use, we need to monitor for the incidence of chlorhexidine
resistance. There is evidence that oral chlorhexidine is effective at
reducing respiratory infections among cardiac surgery patients,
but larger trials need to be done in noncardiac patients to deter-
mine the usefulness of this strategy.
Orally administered systemic decolonizing agents, such as oral
rifampin, may be acceptable for extranasal decolonization of S.
aureus, but it is currently unknown whether systemic oral decolo-
nization is more efficacious than topical decolonization for re-
moving S. aureus. There is also evidence to support decolonization
with SDD and SOD, but more studies are needed to assess the
collateral damage from this strategy, particularly the selection for
drug resistance in Gram-negative organisms.
The strongest evidence for decolonization is among surgical
patients in order to prevent SSIs. The populations that may benefit
the most are patients undergoing cardiac and orthopedic surgery.
According to recent recommendations, decolonization prior to
surgery is considered to be a special approach to prevent SSIs
(155). Thus, it should be strongly considered based on the local
epidemiology of each institution. Acute short-term use of decolo-
nizing agents, such as prior to surgery, is recommended in order to
avoid adverse outcomes such as recolonization and resistance. Re-
sistance to both mupirocin and chlorhexidine has been seen when
they are used over a long time period.
There have been only a few multicenter, randomized trials
evaluating decolonization. Of the few that exist, even fewer have
compared decolonizing agents head-to-head to determine the su-
periority of an agent or a decolonizing protocol. Most studies use
simple before-after quasi-experimental study designs that rely on
historical control groups. That study design may lead to biased
results due to regression to the mean, secular trends, or seasonal
effects. Future research in this field should include large trials
evaluating decolonizing agents in other patient populations such
as patients in ICUs and long-term-care facilities, using standard-
ized methods to measure both colonization and decolonization.
Large randomized trials should also compare newer decolonizing
agents head-to-head against currently used agents.
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